Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06460987
Status:
COMPLETED
Last Update Posted:
2024-06-14
First Post:
2024-05-28
Brief Title:
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
Sponsor:
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Organization:
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Study Overview
Official Title:
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failureAccording to current guideline recommendations there are limited indications for non-steroidal MRAs Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted
Detailed Description:
Primary IgA nephropathy IgAN is an immunopathological diagnostic term for a type of glomerulonephritis characterised by the deposition of IgA or IgA-dominant immune complexes in the glomerular tunica albuginea And in China IgA nephropathy accounts for about 45 of primary glomerular diseases and about 26 of renal biopsies in patients with chronic failure Among them about 15-40 of IgA nephropathy patients progress to renal failure after 10-20 years IgA nephropathy has become one of the main causes of end-stage renal failureThe nonsteroidal salicorticoid receptor antagonist MRA- finerenone reduces the risk of composite renal outcomes ESKD or renal death in patients with type 2 diabetes and CKDThere are limited indications for non-steroidal MRAs Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None